vimarsana.com
Home
Live Updates
Use of ADCs in the Second-Line Treatment of HER2+ mBC : vimarsana.com
Use of ADCs in the Second-Line Treatment of HER2+ mBC
Experts introduce the antibody-drug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) and discuss clinical trial findings and potential use in special patient populations, such as those with brain metastases.
Related Keywords
Sara Hurvitz ,
Melindal Telli ,
Heather Mcarthur ,
,
Breast Cancer ,
Her2 Breast Cancer ,
Her2 Positive Breast Cancer ,
Metastatic Breast Cancer ,
Ther2 ,
Second Line Therapy ,
Taxane ,
Btrastuzumab ,
Trastuzumab Deruxtecan ,
Trastuzumab Emtansine ,
T Dm1 ,
T Dxd ,
Destiny Breast03 ,
Db03 ,
Db 03 ,
Interstitial Lung Disease ,
Ild ,
Capecitabine ,
Blood Brain Barrier ,
Her2climb ,
Brain Metastases ,
Tuxedo 1 ,
Tucatinib ,
vimarsana.com © 2020. All Rights Reserved.